First Name	Last Name	Degree(s)	Affiliation	Country	Email	Group to Mentor	Activities	Specialties/Specialty Area
Kacey	**Anderson**	PhD	Industry	US	akacey1@gmail.com	· Students & Trainees (undergrad, graduate, post-doc) · Early-stage Professionals Industry/Regulatory Track	· Clinical · Research	· PK/PD/DM · Drug Interactions **Specialty Area:** Dr. Anderson is a clinical pharmacologist working in the pharmaceutical industry. She has comprehensive clinical pharmacology experience from Phase 1 to Phase 3 and has been the clinical pharmacology lead on several project teams for inflammation small molecules. She has experience in authoring multiple regulatory submissions, included IND/CTA submissions and NDA/MAA/PMDA submissions.
Vikram	**Arya**	PhD	Government/ Regulatory	US	vikram_arya@yahoo.com	· Early-stage Professionals Industry/Regulatory Track	· Regulatory	· Infectious Disease **Specialty Area:** Dr. Vikram Arya earned his Ph.D. in Pharmaceutics from the University of Florida. He has published articles on drug-drug interactions and impact of transporter modulation on drug disposition and has presented at various conferences. He is a Fellow of the American College of Clinical Pharmacology (ACCP) and currently serves as President-Elect of ACCP. He holds an Adjunct Clinical Professor appointment in the Department of Pharmacy Practice at Mercer University, Atlanta, GA, Adjunct Assistant Professor appointment in the Department of Pharmaceutical Sciences at the University of Tennessee, Adjunct Associate Professor appointment in the Department of Pharmaceutics, University of Florida, and Adjunct Professor appointment in the Department of Pharmacotherapy in the University of North Texas System College of Pharmacy. He serves on the Editorial Board of the Journal of Clinical Pharmacology (JCP) and International Journal of Clinical Pharmacology and Therapeutics (IJCPT).
Mohamed	**Badawi**	PhD	Industry	US	mohamed.badawi@abbvie.com	· Students & Trainees (undergrad, graduate, post-doc) · Early-stage Professionals Industry/Regulatory Track	· Research · Administration/ Management · Teaching	· Cancer Therapies · Drug Interactions · Special Populations **Specialty Area:** Dr. Badawi received his PhD from the Ohio State University and currently works as an Associate Director at AbbVie Inc serving as the clinical pharmacology lead for several oncology early assets including small molecules, monoclonal antibodies and antibody drug conjugates.
Simon	**Berger**	PhD	Industry	US	Simon_Berger@vrtx.com	· Students & Trainees (undergrad, graduate, post-doc) · Academic/Industry Track	· Research	· PK/PD/Drug Metabolism · Pharmacometrics · Clinical Research **Specialty Area:** Dr. Berger worked as a pharmacist in the EU before he went on to earn his PhD in Pharmaceutical Sciences from the University of Florida at the Center for Pharmacometrics and Systems Pharmacology. His academic expertise lies in Biopharmaceutics and Clinical Pharmacology of orally inhaled and nasal drug products. As a Clinical Pharmacologist at Vertex Pharmaceuticals, he specializes in the design, execution, and analysis of early and late phase clinical studies within the field of non-opioid pain therapeutics. As a new member ambassador with ACCP, Dr. Berger has helped many new members navigate their way around the society.
Joe	**Bertino**	PharmD	Consulting	US	sbertino@ix.netcom.com	· Students & Trainees · Academic junior faculty	· Consultant · Other	· Infectious Disease · Pharmacogenomics · Patient Care **Specialty Area:** Dr. Bertino has experience in both Pediatric and Adult Clinical Pharmacology, in patient care, research and teaching. He is currently the Editor-in-Chief of the Journal of Clinical Pharmacology. His expertise included drug metabolism and PK/PD application for drugs.

First Name	Last Name	Degree(s)	Affiliation	Country	Email	Group to Mentor	Activities	Specialties/Specialty Area
Sihem	**Bihorel**	MS, PharmD, PhD	Industry	US	sihem.ait.oudhia@gmail.com	· Students & Trainees (undergrad, graduate, post-doc) · Early-stage Professionals Academic/Industry Track	· Research · Teaching	· PK/PD/DM · Cancer Therapies · Translational Medicine **Specialty Area:** Dr. Sihem Bihorel (née Ait-Oudhia) is a Senior Director at Merck & Co. She holds two Master's degrees in Immunology and Pharmacometrics, a PharmD degree, and a PhD degree from the University Paris Descartes in France. Dr. Bihorel conducted her PhD research in the Department of Pharmaceutical Sciences at SUNY at Buffalo, where she later served as a Postdoctoral Associate and Research Assistant Professor. Prior to joining Merck & Co., Dr. Bihorel was an Assistant Professor at the Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida. Dr. Bihorel is an expert in the end-to-end application of model-informed drug development using various quantitative modeling and simulation approaches across multiple therapeutic areas such as oncology, hematology, immunology, cardio-metabolic diseases, infectious diseases, and drug delivery. She has authored numerous scientific publications in international peer-reviewed journals, book chapters, and presented her work as posters, talks, and webinars at various international conferences. Dr. Bihorel serves on the Editorial Board of the Journal of Pharmacokinetics and Pharmacodynamics and Clinical Pharmacology and Therapeutics. She is also a mentor to many students, postdocs, scholars, and scientists in academia and the pharmaceutical industry.
Angela	**Birnbaum**	PhD	Academia	US	birnb002@umn.edu	· Students & Trainees (undergrad, graduate, post-doc) · Early-stage Professionals Academic Track	· Research · Teaching	· Neurology · PK/PD/DM · Special Populations **Specialty Area:** Dr. Birnbaum is a translational researcher studying the pharmacokinetics of neurological medications using pharmacometrics as a tool, and with an emphasis on neuropharmacology and special populations. She has expertise in several areas including antiseizure medications and drug addiction therapy.
Christine	**Brandquist**	PharmD	Industry	US	Christine.Brandquist@celerion.com	· Students & Trainees (undergrad, graduate, post-doc) · Early-stage Professionals Industry/Regulatory Track	· Clinical · Consultant	· Biostatistics/Clinical Trials · PK/PD/DM · Pharmacometrics **Specialty Area:** Dr. Brandquist a clinical pharmacokineticist with a focus on pharmacokinetic and pharmacodynamic assessments in Phase 1 clinical trials. She is involved in study design development and submission-ready protocol writing, data analysis, and report writing. The types of Phase 1 studies that she typically works on are First-in-Human Single and Multiple Ascending Doses, Bioavailability, Bioequivalence, Food Effect, Drug-Drug Interactions, Renal Impairment, Hepatic Impairment, and Gender/Ethnicity studies. In addition, she has experience in population pharmacokinetics/pharmacometrics. Dr. Brandquist is a long-time Member of ACCP and has served in many roles, including as the Chair of the Membership Committee, and has mentored many young colleagues.
Kristina	**Brooks**	PharmD	Academia	US	kristina.brooks@cuanschutz.edu	· Students & Trainees · Early-stage Professionals Academic Track (1-3 Years)	· Research · Clinical	· PK/PD/DM · Infectious Disease · Special Populations **Specialty Area:** Kristina Brooks, PharmD is Assistant Research Professor at the University of Colorado Anschutz Medical Campus and co-investigator in the Colorado Antiviral Pharmacology Laboratory. Her primary research focus is on the clinical pharmacology of antiviral and tuberculosis medications in children and pregnant women with HIV. Dr. Brooks has extramural funding through NIAID, is involved in multiple studies through the International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) Network, and is a member of the DHHS Perinatal and Pediatric HIV Guidelines Panels.

First Name	Last Name	Degree(s)	Affiliation	Country	Email	Group to Mentor	Activities	Specialties/Specialty Area
Lawrence	**Cohen**	PharmD	Academia	US	lawrence-cohen@att.net	· Students & Trainees · Academic junior faculty	· Consultant · Clinical · Research	· Psychopharmacology · Clinical Research · Translational Medicine **Specialty Area:** Dr. Cohen's research and scholarly interests include development of new/novel treatments for psychiatric disorders, pharmacokinetics and pharmacodynamics of psychotropic medications, geriatric psychopharmacology, pharmacoeconomics and health outcomes, pharmacoepidemiology, health disparities and emergency preparedness (specifically, access and affordability of healthcare during times of crisis).
Jonathan	**Constance**	PhD	Academia	US	jonathan.constance@utah.edu	· Students & Trainees (undergrad, graduate, post-doc) · Early-stage Professionals Academic Track	· Research	· Cancer Therapies · Drug Interactions · Translational Medicine **Specialty Area:** Dr. Constance is a board-accredited clinical pharmacologist with advanced training in molecular biology. His primary focus is on the pharmacokinetic and pharmacodynamic consequences of drug interactions affecting children with cancer. Drug interactions are common among patients with cancer, but interpreting the risks (or benefits) to safety and efficacy require interpretation within genetic, developmental, and pathophysiologic contexts. His research seeks to identify opportunities to optimize drug therapy and improve health outcomes. Dr. Constance is a previous ACCP Student Abstract Award Winner and the winner of the 2015 Wayne A Colburn Award. He currently serves as the Chair of the ACCP Working Group on Early-stage Professionals."
Matthew	**Dufek**	PhD	Industry	US	Matthew.Dufek@abbvie.com	· Students & Trainees (PhD and post-doc) · Early-stage Professionals Industry Track	· Clinical · Administration/ Management	· PK/PD/DM · Clinical Research · Drug Interactions **Specialty Area:** Dr. Dufek is Director of Clinical pharmacology at Abbvie in the department of clinical pharmacology and pharmacometrics (since 2013). IHe is the lead clinical pharmacology representative on the global development teams within the General Medicine Therapeutic Area. Some of the compounds he currently supports are in the therapeutic areas of cystic fibrosis, oncology, anti-infective (HIV and HCV), men's & women's health (endometriosis and fibroids), renal disease, pediatric and mature products. The majority of his responsibilities are leading the development of and strategic planning of clinical development plans for the execution of Phase 1-3 clinical studies within these project teams and review of proposals with executive management and governance committees. Other responsibilities have included, serving as clinical pharmacology team lead and steering committee member for external collaborations between AbbVie and other pharmaceutical development companies (US and Global) and external asset review and due diligences.
Mike	**Fossler**	PharmD, PhD, FCP	Industry	US	michael.fosslerjr@cytel.com	· Students & Trainees (PhD and post-doc) · Early-stage Professionals Industry Track	· Administration/ Management · Research	· PK/PD/DM · Pharmacometrics **Specialty Area:** Michael J. Fossler is Vice-President, Clinical Development and Quantitative Sciences, at Trevena, Inc. From 1995 to 2000, Dr. Fossler was employed by the FDA as a clinical pharmacology reviewer in the Division of Metabolic and Endocrine Drug Products. In 1998, he was promoted to Senior Reviewer, and joined the Pharmacometrics group at FDA, where he was responsible for reviewing and performing population PK/PD analyses. He left the Agency in 2000 and joined the Clinical Pharmacokinetics Group at DuPont Pharmaceuticals, where he had major responsibility for PK/PD analyses in the cardiovascular and anti-inflammatory areas. In November, 2001, he joined GlaxoSmithKline, where he continued to work in the cardiovascular area, and eventually headed a group of nine pharmacometrics scientists. He left GSK in 2015 to assume his present role at Trevena, Inc., where he heads up clinical pharmacology, clinical operations, biostatistics, programming and data management. He received a Pharm. D. (1992) and Ph. D. (1995) degrees from the University of Maryland. Dr. Fossler is a Fellow of the American Foundation for Pharmaceutical Education, a Fellow of the American College of Clinical Pharmacology, a past President of the College and is an Honorary Regent. He holds adjunct faculty appointments at the University of Maryland School of Pharmacy, Mercer University, and the University of North Texas, and is on the faculty of the University of California's American Course on Drug Development and Regulatory Science.

First Name	Last Name	Degree(s)	Affiliation	Country	Email	Group to Mentor	Activities	Specialties/Specialty Area
John	**Foxworth**	PharmD	Academia	US	foxworthj@umkc.edu	· Students & Trainees (PhD and post-doc) · Early-stage Professionals Academia Track	· Teaching · Research	· Cardiovascular Diseases · Cancer Therapies **Specialty Area:** Dr. Foxworth's research interests are in evidence-based medicine. Dr. Foxworth works with students and residents teaching research methodology, biostatistics and evidence-based medicine.
Suzette	**Girgis**	PhD	Industry	US	sgirgis@jazzpharma.com	· Students & Trainees · Early-stage Professionals Industry Track	· Research	· Pharmacokinetics/ Pharmacodynamics/ Drug Metaboliam · Pharmacometrics · Cancer Therapies **Specialty Area:** Dr. Girgis received her PhD from the University of Rhode Island. She has strong drug development experience (more than 20 years) in small molecule, cell therapy and biologics (including bispecifics such as BCMA and GPRC5D) at early and late stage of development, including filing and registration across different therapeutic areas with emphasis on oncology. Her skills include - expert in selecting the dose regimen for First in Human and the Proof of Concept studies, - solid clinical experience in study execution and data interpretation, - strong managerial and mentoring experience - influential leadership skills - oversee the clinical pharmacology strategy of heme compounds - significant contributions to various compounds submissions (such as teclistamab, Velcade, Dacogen, Nulojix) - Due Diligence activities - business and operation strategy.
Vineet	**Goti**	BPharm, PhD	Industry	US	Vineet.Goti@bms.com	· Students & Trainees · Early-stage Professionals Industry Track	· Industry · Drug Development	· Consulting · Industry · Drug Development · Precision Dosing · Population PK · Pharmacometrics · Clinical Pharmacology · Neuroscience · Vancomycin **Specialty Area:** Dr. Vineet Goti is a clinical pharmacology professional specializing in the application of clinical pharmacology and pharmacometric approaches to answer drug development questions and facilitate regulatory approval. Over the last 8 years, he has progressed through roles of increasing responsibility in a contract research organization (CRO) and drug development setting. Spanning various stages of clinical development, he has supported the development of both small molecules and large molecules across a variety of therapeutic areas including infectious diseases, oncology, immunology, fibrosis and neuroscience etc.
Navin	**Goyal**	PhD	Industry	US	NGoyal3@ITS.JNJ.com	· Students & Trainees · Early-stage Professionals Industry/Regulatory	· Research · Clinical	· PK/PD/DM · Pharmacometrics · Translational Medicine **Specialty Area:** Dr. Goyal has 8 years of experience in Clinical Pharmacology and Pharmacometrics working in Industry (GlaxoSmithKline) in different therapy areas. He is happy to share experience and mentor trainees/young professionals of what skills they need to sharpen, what should they expect when joining the industry at entry level positions.

First Name	Last Name	Degree(s)	Affiliation	Country	Email	Group to Mentor	Activities	Specialties/Specialty Area
Oliver	**Grundmann**	PhD	Academia	US	grundman@ufl.edu	· Students & Trainees · Academic junior faculty	· Teaching · Research	· Education · Central Nervous System · Preclinical Research **Specialty Area:** Dr. Grundmann received a bachelor's degree in pharmacy and European pharmacist license from the University of Münster, Germany, in 2004 before beginning his graduate studies at the University of Florida. While continuing his Ph.D. in Pharmaceutical Sciences, he worked for the Forensic Science program after graduating with a master's degree in Forensic Toxicology and minor in Statistics. His research interests include the search for new treatment options from natural products for Central Nervous System and Gastrointestinal diseases such as anxiety and depressive disorders as well as irritable bowel syndrome and cancers of the gastrointestinal tract. He also is interested in the implementation and impact of national and international collaborations for curricular development in the health sciences with an emphasis on distance and online education. Dr. Grundmann serves as the Director and faculty advisor for the online Master of Science and graduate certificate programs in Pharmaceutical Chemistry and Clinical Toxicology at the College of Pharmacy.
Neeraj	**Gupta**	PhD	Industry	US	Neeraj.Gupta@Takeda.com	· Students & Trainees · Early-stage Professions Industry/Regulatory Track	· Research · Clinical	· Pharmacometrics · Cancer Therapies · Regulatory/Scientific Affairs **Specialty Area:** Dr. Gupta is an expert in clinical pharmacology and pharmacometrics and has extensive experience as a drug developer in oncology drug development. He holds a PhD degree in Pharmaceutics from the Univ of Iowa with specialization in pharmacokinetic/pharmacodynamic sciences. He has held positions in the pharmaceutical industry at Abbott and Millennium/Takeda. Currently at Takeda, Dr. Gupta leads a group of PhD-level clinical pharmacologists responsible for representing the discipline on drug development program teams from translational research through late-stage clinical development. He directly serves as the Global Clinical Pharmacology Leader for two of Takeda Oncology's marketed products, the proteasome inhibitor ixazomib for multiple myeloma and the ALK inhibitor brigatinib for ALK+ Non-small cell lung cancer, where his superior scientific and strategic leadership have been central to the development of these drugs. Dr. Gupta has published over 40 peer-reviewed papers in prestigious journals and over 90 abstracts/conference presentations at national and international meetings serving the communities of clinical pharmacology, translational medicine, cancer research, oncology clinical medicine and drug development/regulatory science. He has served as an invited speaker/faculty member or session chair at multiple major national and international meetings and at the FDA on topics ranging from model-informed drug development, proarrhythmic risk assessment in drug development and clinical pharmacology/pharmacometrics in oncology drug development.
Craig	**Hendrix**	PhD	Academia	US	chendrix@jhmi.edu	· Students & Trainees · Early-Stage Professionals Academic Track	· Research · Teaching	· PK/PD/DM · Infectious Disease · Translational Medicine **Specialty Area:** Craig Hendrix is an infectious diseases-trained physician and clinical pharmacologist at Johns Hopkins University where he conducts hands-on clinical studies of drugs for HIV prevention. He has been principal investigator of well over a hundred early phase PK/PD clinical studies as well as protocol pharmacologist for dozens of randomized controlled PK and efficacy trials in several large NIH-funded clinical trials networks. He has enjoyed mentoring medical and graduate students, post-doctoral clinical research fellows, and junior faculty in the context of these clinical studies and regarding their professional careers for over thirty-three years. He served 13 years in the US Air Force prior to coming to the Hopkins faculty, where he is currently the Director of the Division of Clinical Pharmacology, and has enjoyed participation on numerous advisory committees in service to the FDA.

First Name	Last Name	Degree(s)	Affiliation	Country	Email	Group to Mentor	Activities	Specialties/Specialty Area
Matthew	**Hruska**	PharmD, PhD	Industry	US	matthew.hruska.b2@kyowakirin.com	· Early-stage Professionals · Students and Trainees · Industry Track	· Clinical · Research	· PK/PD/DM · Drug Interactions · Pharmacometrics **Specialty Area:** Dr. Hruska is the Vice President, Global Head of Clinical Pharmacology at Kyowa Kirin Inc-US.
Silvia	**Illamola**	PhD	Academia	US	sillamol@umn.edu	· Students & Trainees	· Research	· PK/PD/DM · Special Populations · Pharmacometrics **Specialty Area:** Dr. Illamola's research is focused on clinical pharmacology and pharmacometrics in neonatology and obstetrics. Of special interest is the influence of growth and development of often used medication on the pharmacokinetics and pharmacodynamics in newborns, children and infants. Additionally, her research includes the clinical pharmacology of medications during pregnancy and lactation.
Manoj	**Jadhav**	PhD	Industry	US	manojpjadhav@yahoo.com	· Students & Trainees · Early-stage Professionals Industry/Regulatory Track	· Administration/ Management · Research	· Drug Discovery/Formulations **Specialty Area:** Dr. Jadhav is a PhD in Pharmaceutical Technology and a trained clinical pharmacologist. He has worked on both non-clinical and clinical drug development programs in infectious diseases and cardiovascular diseases both in India and USA. He has published over 25 research papers in peer reviewed journals and has worked at both industry and academia.
Catherijne	**Knibbe**	PhD	Academia	EU	c.knibbe@antoniusziekenhuis.nl	· Students & Trainees · Early-stage Professionals Industry Track	· Clinical · Research	· Special Populations · PK/PD/DM · Pharmacometrics **Specialty Area:** Dr. Knibbe is an esteemed Professor of Individualized Drug Treatment, Division of Systems Pharmacology and Pharmacy, LACDR at the Leiden University & a Clinical Pharmacologist-Hospital Pharmacist (member Daily Board), St Antonius Hospital Nieuwegein. She has extensive international connections and a devotion to teaching the next generation of clinical pharmacologists.
Abhinav	**Kurumaddali**	PhD	Industry	US	abhinav.kurumaddali@takeda.com	· Students & Trainees · Early-stage Professionals Industry /Regulatory Track	· Research	· Pharmacokinetics/ Pharmacodynamics/ Drug Metabolism · Pharmacometrics · Cancer Therapies **Specialty Area:** Dr. Abhinav Kurumaddali , PhD, is Associate Director of Quantitative Clinical Pharmacology at Takeda Pharmaceuticals USA.
Jeremiah	**Momper**	PharmD, PhD	Academia	US	jmomper@ucsd.edu	· Students & Trainees · Early-stage Professionals Academic Track (1-10 Years)	· Research · Teaching	· PK/PD/DM · Special Populations · Clinical Research **Specialty Area:** Jeremiah Momper, PharmD, PhD is an Associate Professor at the Skaggs School of Pharmacy and Pharmaceutical Sciences at UC San Diego. Dr. Momper's research focuses on the application of quantitative pharmacology approaches to optimize the development and clinical use of drugs. Current research directions include evaluation of potential therapies for HIV infection in infants and pregnant women and the use of model-based methods to support scientific decision making in drug development. Dr. Momper directs the Translational Pharmacology and Bioanalysis Laboratory concentrated on novel mass spectrometry-based analytical methods, in vitro ADME assays, and pre-clinical and clinical pharmacokinetic studies.

First Name	Last Name	Degree(s)	Affiliation	Country	Email	Group to Mentor	Activities	Specialties/Specialty Area
Ahmed	**Nader**	PhD	Industry	US	ahmed.m.nader@gsk.com	· Students & Trainees · Early-stage Professionals Industry/Regulatory Track	· Research · Other	· Pharmacometrics · PK/PD/DM · Immunology/Rheumatology **Specialty Area:** Dr. Nader is the Assoc Director of Clinical Pharmacology Modeling & Simulation at GlaxoSmithKline.
Vidya	**Perera**	PhD	Industry	EU	vid.perera22@gmail.com	· Students & Trainees · Early-stage Professionals Industry/Regulatory Track	· Clinical · Reserch	· Cardiovascular Diseases · Clinical Research · Biostatistics/ Pharmaceutical R&D **Specialty Area:** Dr. Perera is the Vice President & Global Head of Early Clinical Development at Bayer Healthcare Pharmaceuticals Inc in Germany. He is a PhD-trained pharmaceutical executive and clinical pharmacologist with over 15 years of specialized experience in drug development across academic and industry settings. Demonstrated leadership in translational medicine and early clinical development with direct oversight of multidisciplinary teams and complex cardiovascular programs from discovery through to Life Cycle Management. As Vice President and Head of Early Clinical Development in Cardiovascular, Renal and Immunology at Bayer and former Head of Cardiovascular Clinical Pharmacology and Pharmacometrics at Bristol Myers Squibb, he has led multiple high-impact initiatives in cardiovascular, virology and immunology translational strategy, dose selection, and precision medicine implementation. Of note, has played a significant role in the development and innovation associated with Milvexian, Apixaban, Belatacept, Abatacept, Mavcamten and Finerenone. Published extensively in translational medicine, clinical pharmacology and pharmacometrics with over 45 peerreviewed manuscripts and numerous presentations at major clinical and clinical pharmacology conferences including election as a Fellow of the American College of Cardiology. Proven track record in regulatory negotiations, innovative trial design, and fostering scientific rigor across the drug development lifecycle. Passionate about advancing evidence-based cardiovascular care through integrated clinical, quantitative, and translational insights.
Cristina	**Salcianu**	PharmD, MS	Industry	US	cristinna.salcianu@gmail.com	· Students & Trainees · Early-stage Professionals Industry/Regulatory Track	· Research · Regulatory · Consulting	· PK/PD/DM · Pharmacometrics · Clinical Reserch **Specialty Area:** Dr. Salcianu is a pharmacokinetics scientist working in industry with a PharmD and an MSc in Regulatory Affairs, and has experience spanning preclinical and clinical drug development, clinical pharmacology, pharmacometrics, and regulatory science. Her work has included support of first-in-human through Phase 3 clinical trials, including food-effect, drug–drug interaction, bioavailability/bioequivalence, renal and hepatic impairment studies, as well as ADME characterization, noncompartmental analysis, concentration–QT analyses, and model-informed drug development. In addition to her professional role, she currently serve as a mentor in the AAPS Mentoring Program, where she mentors a PhD student, and also contribute as a curriculum vitae (CV) and letter of intent (LOI) reviewer for ACCP. These experiences have strengthened my ability to provide structured, constructive guidance on scientific development, career planning, and professional communication.

First Name	Last Name	Degree(s)	Affiliation	Country	Email	Group to Mentor	Activities	Specialties/Specialty Area
Ahmed	**Salem**	PhD	Industry	US	ahmed.salem@abbvie.com	· Early-stage Professionals Industry Track	· Clinical · Research	· PK/PD/DM · Infectious Disease · Pharmacometrics **Specialty Area:** Dr. Ahmed Salem is an associate director of Clinical Pharmacology and Pharmacometrics at AbbVie, North Chicago, USA, where he leads a group of clinical pharmacologists supporting the development of targeted anti-cancer agents. Dr. Salem is a pharmacist and holds a PhD in Clinical Pharmacology from University of Minnesota with minor in Biostatistics. Dr. Salem's research at University of Minnesota focused on pharmacometric analyses of anti-HIV and anti-MRSA agents. In the industry, Dr. Salem has supported the clinical development of small and large molecules in the oncology, virology and women's health therapeutic areas. Dr. Salem has contributed to the approval of several new and supplemental drug applications and marketing authorization applications. His most recent accomplishment was leading the clinical pharmacology strategy for the first-in-class BCL-2 inhibitor; venetoclax, contributing to its approval in the US and EU. Dr. Salem has published over 80 peer-reviewed publications including 33 original research articles. Dr. Salem serves on the STYP Committee of the American College of Clinical Pharmacology (ACCP) and on the publications committee of the International Society of Pharmacometrics (ISoP). He is also a peer review for numerous clinical pharmacology journals and is a member of the Rho Chi pharmacy Phi Kappa Phi Honor societies.
Mohamadi	**Sarkar**	MPharm, PhD, FCCP	Industry	US	Mohamadi.Sarkar@altria.com	· All levels Looking for a long term mentoring relationship	· Clinical · Regulatory	· Biomarkers/Precision Medicine · Biostatistics/Clinical Trials · Clinical Research **Specialty Area:** Dr. Sarkar is a Fellow of Scientific Strategy at Altria Client Services LLC, and is an Affiliate Professor of Clinical Pharmacology at the Medical College of Virginia at VCU. He provides strategic direction towards developing the science and evidence for regulatory submissions for non-combustible tobacco products for Altria's tobacco operating companies. He has authored more than 100 scientific peer-reviewed publications and presentations at scientific meetings. Dr. Sarkar has also participated in multiple seminar presentations and authored a variety of scientific book chapters related to his areas of expertise.
Aarti	**Sawant Basak**	PhD	Industry	US	aarti.sawant@astrazeneca.com	· Students & Trainees · Early-stage Professionals Industry Track	· Clinical · Research · Regulatory	· PK/PD/DM · Special Populations · Clinical Research **Specialty Area:** Dr. Sawant is an industry expert with experience in clinical pharmacology. She has extensive experience in end-to-end drug development with 17 years spanning across different therapeutic areas including oncology, neuroscience, immunology, and cardiovascular and metabolic disorders. Dr. Sawant received her PhD in University of Illinois (UIC) College of Pharmacy, UIC NIH Botanical center evaluating hepatotoxicity of natural products and dietary supplement. After completing her Ph.D in Dec 2006, Dr. Sawant spent 15+ years at Pfizer initially in the drug metabolism and pharmacodynamics group and later on in Clinical Pharmacology. Currently at AstraZeneca, Dr. Sawant supports oncology programs across different modalities from candidate nomination through life cycle management, including approved products (e.g.Tagrisso). In this role as a global clinical pharmacology lead, she drives dose optimization strategies in drug development. She also serves as an adjunct faculty at the University of Arizona R.K. Coit College of Pharmacy and mentors students and staff within and through societies externally (e.g. ASCPT and HBA). She is a reviewer for journals within the community and serves as an editorial board member at DMD since 2018. She has published peer-reviewed articles in clinical pharmacology, modeling and simulation, drug interactions, combination, translational pharmacology, PK/PD, and PBPK.

First Name	Last Name	Degree(s)	Affiliation	Country	Email	Group to Mentor	Activities	Specialties/Specialty Area
Mohamadi	**Shebley**	PhD	Industry	US	mohamad.shebley@abbvie.com	· Students & Trainees · Early-stage Professionals Industry/Regulatory Track	· Research · Clinical	· PK/PD/DM · Drug Interactions · Pharmacometrics **Specialty Area:** Dr. Shebley received his PhD in Pharmacology from the Univ of Michigan, with focus on drug-drug interaction. He joined industry after graduation and worked across divisions of drug discovery and development, spanning DMPK, translational science, modeling and simulation, and clinical pharmacology and pharmacometrics. He is currently serving as Clinical Pharmacology Group Leader supporting PhD/PharmD clinical pharmacologists working across development projects ranging from FIH to commercialization in the Specialty therapeutic area (general medicine/infectious disease), with previous experience in oncology. He became a Fellow of Clinical Pharmacology in ACCP in 2019 and serves on the ACCP Membership Committee and ACCP 2022 Annual Meeting Programming Committee.
Suneet	**Shukla**	PhD	Industry	US	ssuneet@yahoo.com	· Students & Trainees · Early-stage Professionals · Industry/Regulatory Track	· Regulatory	· PK/PD/DM · Pharmacometrics **Specialty Area:** Dr Suneet Shukla is a pharmacist by educational training with a PhD in molecular pharmacology, studying drug transporters, and their role in fungal infections, cancer drug resistance, and altering ADME-toxicity of drugs. He worked at the US Food and Drug Administration in the Offices of New Drug Products, Generic Drugs and Clinical Pharmacology and served as reviewer and acting team lead where his responsibilities included the review of INDs, NDAs, ANDAs, and other regulatory submissions from a biopharmaceutics, bioequivalence and clinical pharmacology perspectives. He has published several highly cited research and review articles, received patents, awards from NIH and FDA. He has served on panels evaluating research grants submitted to NIH and FDA, mentored several undergraduate, graduate and post-doctoral trainees and has served as the lead instructor of the medical pharmacology course at the Foundation for Advanced Education in the Sciences (FAES) Graduate School, NIH. He is currently working as Director (Clinical Pharmacology) at Boehringer Ingelheim Pharmaceuticals, USA.
Ravi Shankar	**Singh**	PhD	Industry	US	RaviShankar.Singh@pfizer.com	· Students & Trainees · Early-stage Professionals · Academic/Industry Track	· Research	· Drug Discovery/Formulation · PK/PD/Drug Metabolism **Specialty Area:** Dr. Singh is currently a Senior Director of Clinical Pharmacology at Pfizer Inc. Before Pfizer, he held various positions at Abbvie Inc, Univ of Florida, Central Drug Research Institute (Lucknow, India) and Dr. Reddy's lab (Hyderabad, India). His experiences span different phases of drug discovery and development starting from preclinical drug discovery to the post-approval product maintenance in anti-infective and inflammation and Immunology therapeutic areas. His interest lies in implementing innovative clinical pharmacology, MIDD and AI/ML strategies in the drug development.
Meenakshi	**Srinivasan**	PharmD	Industry	US	meenakshi.x.srinivasan@gsk.com	· Students & Trainees · PharmD/grad students · Industry Track	· Research	· Pharmacometrics · Outcomes Research/ Pharmacoepidemiology · Biostatistics/Clinical Trials **Specialty Area:** Meenakshi Srinivasan received her PharmD from Manipal University, India and subsequently received training in clinical pharmacometrics and pharmacoeconomics as a postdoctoral research associate at the University of North Texas health Science Center at Fort Worth, TX. Following this, she was a University of Florida-GlaxoSmithKline postdoctoral fellow in pharmacokinetics/pharmacodynamics and gained experience in antibiotic drug development. Currently, she works in the Clinical Pharmacology, Modeling and Simulation (CPMS) team at GSK, Collegeville, PA supporting oncology drug development. She is determined and excited to mentor students and trainees who wish to pursue a career in clinical pharmacology in the pharmaceutical industry.

First Name	Last Name	Degree(s)	Affiliation	Country	Email	Group to Mentor	Activities	Specialties/Specialty Area
Amir	**Youssef**	PhD	Industry	US	amir.s.youssef@gsk.com	· Early-stage Professionals Industry /Regulatory Track	· Clinical · Research	· PK/PD · Pharmacometrics · Infectious Disease **Specialty Area:** Dr. Youssef has been serving as the Director of Clinical Pharmacology Modeling & Simulation at GlaxoSmithKline since 2020. Prior to this role, he spent six years working as a clinical pharmacology consultant, gaining extensive experience in drug development. Throughout his career, Dr. Youssef has worked on both small and large molecules across early and late-stage clinical trials. He also specializes in strategy and modeling to support pediatric studies.